Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1120

1.

Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.

Trocòniz IF, Garrido MJ, Segura C, Cendrós JM, Principe P, Peraire C, Obach R.

Cancer Chemother Pharmacol. 2006 Jun;57(6):727-35. Epub 2005 Oct 28.

PMID:
16261364
2.

Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.

Chabot GG, Armand JP, Terret C, de Forni M, Abigerges D, Winograd B, Igwemezie L, Schacter L, Kaul S, Ropers J, Bonnay M.

J Clin Oncol. 1996 Jul;14(7):2020-30.

PMID:
8683232
3.

A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours.

Scott L, Soepenberg O, Verweij J, de Jonge MJ, Th Planting AS, McGovern D, Principe P, Obach R, Twelves C.

Ann Oncol. 2007 Mar;18(3):569-75.

4.

A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy.

Graham JS, Falk S, Samuel LM, Cendros JM, Evans TR.

Cancer Chemother Pharmacol. 2009 Apr;63(5):945-52. doi: 10.1007/s00280-008-0795-6. Epub 2008 Jul 25.

PMID:
18654747
5.

Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.

Gelderblom H, Salazar R, Verweij J, Pentheroudakis G, de Jonge MJ, Devlin M, van Hooije C, Seguy F, Obach R, Pruñonosa J, Principe P, Twelves C.

Clin Cancer Res. 2003 Sep 15;9(11):4101-7.

6.

Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.

Zhou H, Choi L, Lau H, Bruntsch U, Vries EE, Eckhardt G, Oosterom AT, Verweij J, Schran H, Barbet N, Linnartz R, Capdeville R.

J Clin Pharmacol. 2000 Mar;40(3):275-83.

PMID:
10709156
7.

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.

Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D.

J Clin Oncol. 1995 Jan;13(1):210-21.

PMID:
7799022
8.

A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.

Pinguet F, Culine S, Bressolle F, Astre C, Serre MP, Chevillard C, Fabbro M.

Clin Cancer Res. 2000 Jan;6(1):57-63.

9.

Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.

Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Alberts SA, Schaaf LJ, Elfring G, Miller LL.

Clin Cancer Res. 2000 Jun;6(6):2236-44.

10.

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.

Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boué A, Mahjoubi M, Clavel M.

Ann Oncol. 1995 Feb;6(2):133-40.

PMID:
7786821
11.

Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.

Royce ME, Hoff PM, Dumas P, Lassere Y, Lee JJ, Coyle J, Ducharme MP, De Jager R, Pazdur R.

J Clin Oncol. 2001 Mar 1;19(5):1493-500.

PMID:
11230496
12.

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.

Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Hérait P, Armand JP, Bugat R, et al.

Ann Oncol. 1995 Feb;6(2):141-51.

PMID:
7786822
13.

Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.

Posey JA 3rd, Saif MW, Carlisle R, Goetz A, Rizzo J, Stevenson S, Rudoltz MS, Kwiatek J, Simmons P, Rowinsky EK, Takimoto CH, Tolcher AW.

Clin Cancer Res. 2005 Nov 1;11(21):7866-71.

14.

Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.

Herben VM, van Gijn R, Schellens JH, Schot M, Lieverst J, Hillebrand MJ, Schoemaker NE, Porro MG, Beijnen JH, ten Bokkel Huinink WW.

J Clin Oncol. 1999 Jun;17(6):1906-14.

PMID:
10561232
15.

Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.

Schöffski P, Thate B, Beutel G, Bolte O, Otto D, Hofmann M, Ganser A, Jenner A, Cheverton P, Wanders J, Oguma T, Atsumi R, Satomi M.

Ann Oncol. 2004 Apr;15(4):671-9.

16.

Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.

Berg SL, Blaney SM, Adamson PC, O'Brien M, Poplack DG, Arndt C, Blatt J, Balis FM.

J Clin Oncol. 1998 Jan;16(1):181-6.

PMID:
9440741
17.
18.

Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.

Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA, Stephenson JA Jr, Hodges S, Kraynak MA, Staton BA, Elfring GL, Locker PK, Miller LL, Von Hoff DD, Rothenberg ML.

J Clin Oncol. 1999 Feb;17(2):685-96.

PMID:
10080615
19.

Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.

Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, Krailo M, Reaman G, Hammond D, Poplack DG.

Cancer Res. 1993 Mar 1;53(5):1032-6.

20.
Items per page

Supplemental Content

Write to the Help Desk